Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab

  • Technology appraisal guidance
  • TA202
  • Published: 

This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra).

Ofatumumab will continue to be available for people who need it. Contact Clinigen at [email protected] or 01932 842100 for details.